Evidence map›Paper›PMID 37515192›Full record

ArticleViruses2023

Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in Spain.

Adriana Palom, Edurne Almandoz, Antonio Madejón, Ariadna Rando-Segura, Ylenia Pérez-Castaño, Judit Vico, Sara Gándara, Naranbaatar Battulga, Jordi Gómez-I-Prat, Mar Riveiro-Barciela and 3 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Adriana PalomDepartamento de Hepatología, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0002-0130-1302
Edurne AlmandozDepartamento de Enfermedades Gastrointestinales, Hospital Universitario Donostia, Instituto de Investigación Biodonostia, 20014 San Sebastian, Spain.
Antonio MadejónCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, 28029 Madrid, Spain.ORCID 0000-0002-6564-0434
Ariadna Rando-SeguraCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, 28029 Madrid, Spain.
Ylenia Pérez-CastañoDepartamento de Digestivo, Hospital Bidasoa de Hondarribia, Instituto de Investigación Biodonostia, 20280 San Sebastian, Spain.
Judit VicoDepartamento de Hepatología, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Sara GándaraDepartamento de Hepatología, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Naranbaatar BattulgaDepartamento de Hepatología, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Jordi Gómez-I-PratEquipo de Salud Pública y Comunitaria (ESPIC), Unidad de Salud Internacional Drassanes-Hospital Vall d'Hebron, 08001 Barcelona, Spain.
Mar Riveiro-BarcielaDepartamento de Hepatología, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.ORCID 0000-0001-9309-2052
Juan Arenas Ruiz-TapiadorCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, 28029 Madrid, Spain.
Javier García-SamaniegoCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, 28029 Madrid, Spain.
Maria ButiDepartamento de Hepatología, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Vall d'Hebron Hospital Universitari · ESBiogipuzkoa Health Research Institute · ESHospital Universitario La Paz · ESPoliclínica Gipuzkoa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mongolia has one of the highest viral hepatitis infection (B, C, and D) rates in the world. The aims of this study were to increase awareness of this disease and promote viral hepatitis screening in the Mongolian community living in Spain. Through a native community worker, Mongolian adults were invited to a community program consisting of an educational activity, an epidemiological questionnaire, and rapid point-of-care testing for hepatitis B and C. In those testing positive, blood extraction was performed to determine serological and virological parameters. In total, 280 Mongolians were invited to the program and 222 (79%) attended the event: 139 were women (63%), mean age was 42 years, and 78 (35%) had viral hepatitis risk factors. Testing found 13 (5.8%) anti-HCV-positive individuals, 1 with detectable HCV RNA (0.5%), 8 HBsAg-positive (3.6%), and 7 with detectable HBV DNA (3.1%). One additional individual had HBV/HCV co-infection with detectable HBV DNA and HCV RNA. Two subjects had hepatitis B/D co-infection (0.9%). The knowledge questionnaire showed a 1.64/8-point (20.5%) increase in correct answers after the educational activity. In summary, a viral hepatitis community program was feasible and widely accepted. It increased awareness of this condition in the Mongolian community in Spain and led to linkage to care in 22 participants, 50% of whom were unaware of their infection.

Indexed as

CoinfectionHepatitis AHepatitis BHepatitis CHepatitis DAdultDNA, ViralFemaleHepatitis B Surface AntigensHepatitis B virusHepatitis C AntibodiesHumansMalePrevalenceRNASpainDNA, ViralHepatitis B Surface AntigensHepatitis C AntibodiesRNAcommunity programMongolian communityviral hepatitis awarenessviral hepatitis screening

Identifiers

PMID37515192
PMCPMC10384786
OpenAlexW4383376740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.